PLK1 Regulation of Airway Smooth Muscle

Information

  • Research Project
  • 10205669
  • ApplicationId
    10205669
  • Core Project Number
    R01HL130304
  • Full Project Number
    2R01HL130304-05
  • Serial Number
    130304
  • FOA Number
    PA-20-185
  • Sub Project Id
  • Project Start Date
    7/1/2016 - 8 years ago
  • Project End Date
    3/31/2025 - a month from now
  • Program Officer Name
    LU, JINING
  • Budget Start Date
    4/10/2021 - 3 years ago
  • Budget End Date
    3/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    05
  • Suffix
  • Award Notice Date
    4/7/2021 - 3 years ago
Organizations

PLK1 Regulation of Airway Smooth Muscle

The contractility and growth of airway smooth muscle play an important role in the pathogenesis of airway hyperresponsiveness and smooth muscle layer thickening, cardinal features of asthma that affects nearly 250-300 million people worldwide. The mechanisms underlying these biological and pathological processes are not fully elucidated. Nestin is a type VI intermediate filament protein that has been implicated in progenitor cell functions and cancer pathogenesis. The functional role of nestin in airway smooth muscle is largely unknown. Pilot studies have shown that nestin may contribute to the regulation of smooth muscle contraction and proliferation. In Aim 1, we will determine the role of nestin in regulating airway smooth muscle contractility and cytoskeletal signaling. In Aim 2, we will assess the role and mechanism of nestin in airway smooth muscle proliferation and the growth factor-mediated pathways. In Aim 3, the potential role of nestin-associated cellular processes in human asthma will be determined. The role of nestin in allergen-induced asthma will also be evaluated in vivo. Completion of these studies should advance our knowledge regarding functional role and mechanism of nestin and cytoskeletal signaling in smooth muscle contractility and growth in vitro, and asthma pathogenesis in vivo. Obtaining this knowledge will facilitate the development of new therapy to treat asthma.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    2
  • Direct Cost Amount
    267034
  • Indirect Cost Amount
    168231
  • Total Cost
    435265
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    838
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NHLBI:435265\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    LCMI
  • Study Section Name
    Lung Cellular, Molecular, and Immunobiology Study Section
  • Organization Name
    ALBANY MEDICAL COLLEGE
  • Organization Department
    OTHER BASIC SCIENCES
  • Organization DUNS
    190592162
  • Organization City
    ALBANY
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    122083479
  • Organization District
    UNITED STATES